The effect of resveratrol supplementation on serum levels of asymmetric de-methyl-arginine and paraoxonase 1 activity in patients with type 2 diabetes: A randomized, double-blind controlled trial

Mahtab Tabatabaie; Shima Abdollahi; Amin Salehi-Abargouei; Cain C T Clark; Elham Karimi-Nazari; Hossein Fallahzadeh; Masoud Rahmanian; Hassan Mozaffari-Khosravi

doi:10.1002/ptr.6655

The effect of resveratrol supplementation on serum levels of asymmetric de-methyl-arginine and paraoxonase 1 activity in patients with type 2 diabetes: A randomized, double-blind controlled trial

Mahtab Tabatabaie, Shima Abdollahi, Amin Salehi-Abargouei, Cain C T Clark, Elham Karimi-Nazari, Hossein Fallahzadeh, Masoud Rahmanian, Hassan Mozaffari-Khosravi

Research output: Contribution to journal › Article › peer-review

23 Citations (Scopus)

129 Downloads (Pure)

Abstract

The present study sought to investigate the effect of micronized resveratrol supplementation on serum levels of asymmetric de-methyl-arginine (ADMA) and paraoxonase-1 (PON1) activity in patients with type 2 diabetes (T2D). In this double-blinded randomized trial, 76 patients with T2D were recruited. Participants were randomly assigned to consume 1,000 mg resveratrol or placebo capsules (methylcellulose) per day, for 8 weeks. Serum levels of ADMA and PON1 enzyme activity were measured at the beginning and end of the intervention using the enzyme-linked immunosorbent assay method. In total, 71 participants completed the study. Our results showed that resveratrol significantly decreased serum levels of ADMA (-0.16 ± 0.11, p < .001) and improved PON1 enzyme activity (15.39 ± 13.99, p < .001) compared with placebo, after adjusting for confounding factors (age, sex, and baseline body mass index). Our findings suggest that 8-week resveratrol supplementation may produce beneficial effects on serum levels of ADMA and PON1 enzyme activity in patients with T2DM. However, further research is needed to confirm the veracity of these results.

Original language	English
Pages (from-to)	2023-2031
Number of pages	9
Journal	Phytotherapy Research
Volume	34
Issue number	8
Early online date	6 Mar 2020
DOIs	https://doi.org/10.1002/ptr.6655
Publication status	Published - 1 Aug 2020

Bibliographical note

This is the peer reviewed version of the following article: Tabatabaie, M, Abdollahi, S, Salehi-Abargouei, A, Clark, CCT, Karimi-Nazari, E, Fallahzadeh, H, Rahmanian, M & Mozaffari-Khosravi, H 2020, 'The effect of resveratrol supplementation on serum levels of asymmetric de-methyl-arginine and paraoxonase 1 activity in patients with type 2 diabetes: A randomized, double-blind controlled trial', Phytotherapy Research, vol. 34, no. 8, pp. 2023-2031., which has been published in final form at https://onlinelibrary.wiley.com/doi/abs/10.1002/ptr.6655. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

Keywords

ADMA
PON1 protein
resveratrol
type 2 diabetes mellitus

ASJC Scopus subject areas

Pharmacology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/ptr.6655

Post-PrintAccepted author manuscript, 507 KB

Cite this

Tabatabaie, M., Abdollahi, S., Salehi-Abargouei, A., Clark, C. C. T., Karimi-Nazari, E., Fallahzadeh, H., Rahmanian, M., & Mozaffari-Khosravi, H. (2020). The effect of resveratrol supplementation on serum levels of asymmetric de-methyl-arginine and paraoxonase 1 activity in patients with type 2 diabetes: A randomized, double-blind controlled trial. Phytotherapy Research, 34(8), 2023-2031. https://doi.org/10.1002/ptr.6655

The effect of resveratrol supplementation on serum levels of asymmetric de-methyl-arginine and paraoxonase 1 activity in patients with type 2 diabetes: A randomized, double-blind controlled trial. / Tabatabaie, Mahtab; Abdollahi, Shima; Salehi-Abargouei, Amin et al.
In: Phytotherapy Research, Vol. 34, No. 8, 01.08.2020, p. 2023-2031.

Research output: Contribution to journal › Article › peer-review

Tabatabaie, M, Abdollahi, S, Salehi-Abargouei, A, Clark, CCT, Karimi-Nazari, E, Fallahzadeh, H, Rahmanian, M & Mozaffari-Khosravi, H 2020, 'The effect of resveratrol supplementation on serum levels of asymmetric de-methyl-arginine and paraoxonase 1 activity in patients with type 2 diabetes: A randomized, double-blind controlled trial', Phytotherapy Research, vol. 34, no. 8, pp. 2023-2031. https://doi.org/10.1002/ptr.6655

Tabatabaie M, Abdollahi S, Salehi-Abargouei A, Clark CCT, Karimi-Nazari E, Fallahzadeh H et al. The effect of resveratrol supplementation on serum levels of asymmetric de-methyl-arginine and paraoxonase 1 activity in patients with type 2 diabetes: A randomized, double-blind controlled trial. Phytotherapy Research. 2020 Aug 1;34(8):2023-2031. Epub 2020 Mar 6. doi: 10.1002/ptr.6655

@article{70c0eda6b943441e80cacd58179b1de0,

title = "The effect of resveratrol supplementation on serum levels of asymmetric de-methyl-arginine and paraoxonase 1 activity in patients with type 2 diabetes: A randomized, double-blind controlled trial",

abstract = "The present study sought to investigate the effect of micronized resveratrol supplementation on serum levels of asymmetric de-methyl-arginine (ADMA) and paraoxonase-1 (PON1) activity in patients with type 2 diabetes (T2D). In this double-blinded randomized trial, 76 patients with T2D were recruited. Participants were randomly assigned to consume 1,000 mg resveratrol or placebo capsules (methylcellulose) per day, for 8 weeks. Serum levels of ADMA and PON1 enzyme activity were measured at the beginning and end of the intervention using the enzyme-linked immunosorbent assay method. In total, 71 participants completed the study. Our results showed that resveratrol significantly decreased serum levels of ADMA (-0.16 ± 0.11, p < .001) and improved PON1 enzyme activity (15.39 ± 13.99, p < .001) compared with placebo, after adjusting for confounding factors (age, sex, and baseline body mass index). Our findings suggest that 8-week resveratrol supplementation may produce beneficial effects on serum levels of ADMA and PON1 enzyme activity in patients with T2DM. However, further research is needed to confirm the veracity of these results.",

keywords = "ADMA, PON1 protein, resveratrol, type 2 diabetes mellitus",

author = "Mahtab Tabatabaie and Shima Abdollahi and Amin Salehi-Abargouei and Clark, {Cain C T} and Elham Karimi-Nazari and Hossein Fallahzadeh and Masoud Rahmanian and Hassan Mozaffari-Khosravi",

note = "This is the peer reviewed version of the following article: Tabatabaie, M, Abdollahi, S, Salehi-Abargouei, A, Clark, CCT, Karimi-Nazari, E, Fallahzadeh, H, Rahmanian, M & Mozaffari-Khosravi, H 2020, 'The effect of resveratrol supplementation on serum levels of asymmetric de-methyl-arginine and paraoxonase 1 activity in patients with type 2 diabetes: A randomized, double-blind controlled trial', Phytotherapy Research, vol. 34, no. 8, pp. 2023-2031., which has been published in final form at https://onlinelibrary.wiley.com/doi/abs/10.1002/ptr.6655. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.",

year = "2020",

month = aug,

day = "1",

doi = "10.1002/ptr.6655",

language = "English",

volume = "34",

pages = "2023--2031",

journal = "Phytotherapy Research",

issn = "0951-418X",

publisher = "Wiley",

number = "8",

}

TY - JOUR

T1 - The effect of resveratrol supplementation on serum levels of asymmetric de-methyl-arginine and paraoxonase 1 activity in patients with type 2 diabetes

T2 - A randomized, double-blind controlled trial

AU - Tabatabaie, Mahtab

AU - Abdollahi, Shima

AU - Salehi-Abargouei, Amin

AU - Clark, Cain C T

AU - Karimi-Nazari, Elham

AU - Fallahzadeh, Hossein

AU - Rahmanian, Masoud

AU - Mozaffari-Khosravi, Hassan

N1 - This is the peer reviewed version of the following article: Tabatabaie, M, Abdollahi, S, Salehi-Abargouei, A, Clark, CCT, Karimi-Nazari, E, Fallahzadeh, H, Rahmanian, M & Mozaffari-Khosravi, H 2020, 'The effect of resveratrol supplementation on serum levels of asymmetric de-methyl-arginine and paraoxonase 1 activity in patients with type 2 diabetes: A randomized, double-blind controlled trial', Phytotherapy Research, vol. 34, no. 8, pp. 2023-2031., which has been published in final form at https://onlinelibrary.wiley.com/doi/abs/10.1002/ptr.6655. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

PY - 2020/8/1

Y1 - 2020/8/1

N2 - The present study sought to investigate the effect of micronized resveratrol supplementation on serum levels of asymmetric de-methyl-arginine (ADMA) and paraoxonase-1 (PON1) activity in patients with type 2 diabetes (T2D). In this double-blinded randomized trial, 76 patients with T2D were recruited. Participants were randomly assigned to consume 1,000 mg resveratrol or placebo capsules (methylcellulose) per day, for 8 weeks. Serum levels of ADMA and PON1 enzyme activity were measured at the beginning and end of the intervention using the enzyme-linked immunosorbent assay method. In total, 71 participants completed the study. Our results showed that resveratrol significantly decreased serum levels of ADMA (-0.16 ± 0.11, p < .001) and improved PON1 enzyme activity (15.39 ± 13.99, p < .001) compared with placebo, after adjusting for confounding factors (age, sex, and baseline body mass index). Our findings suggest that 8-week resveratrol supplementation may produce beneficial effects on serum levels of ADMA and PON1 enzyme activity in patients with T2DM. However, further research is needed to confirm the veracity of these results.

AB - The present study sought to investigate the effect of micronized resveratrol supplementation on serum levels of asymmetric de-methyl-arginine (ADMA) and paraoxonase-1 (PON1) activity in patients with type 2 diabetes (T2D). In this double-blinded randomized trial, 76 patients with T2D were recruited. Participants were randomly assigned to consume 1,000 mg resveratrol or placebo capsules (methylcellulose) per day, for 8 weeks. Serum levels of ADMA and PON1 enzyme activity were measured at the beginning and end of the intervention using the enzyme-linked immunosorbent assay method. In total, 71 participants completed the study. Our results showed that resveratrol significantly decreased serum levels of ADMA (-0.16 ± 0.11, p < .001) and improved PON1 enzyme activity (15.39 ± 13.99, p < .001) compared with placebo, after adjusting for confounding factors (age, sex, and baseline body mass index). Our findings suggest that 8-week resveratrol supplementation may produce beneficial effects on serum levels of ADMA and PON1 enzyme activity in patients with T2DM. However, further research is needed to confirm the veracity of these results.

KW - ADMA

KW - PON1 protein

KW - resveratrol

KW - type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=85081370077&partnerID=8YFLogxK

U2 - 10.1002/ptr.6655

DO - 10.1002/ptr.6655

M3 - Article

C2 - 32144833

SN - 0951-418X

VL - 34

SP - 2023

EP - 2031

JO - Phytotherapy Research

JF - Phytotherapy Research

IS - 8

ER -

The effect of resveratrol supplementation on serum levels of asymmetric de-methyl-arginine and paraoxonase 1 activity in patients with type 2 diabetes: A randomized, double-blind controlled trial

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this